Cell-Based Therapies for Myocardial Regeneration in Heart Failure: 20 Years of Debate

The functional benefits were identified in both models of transmural infarction and Chagasic cardiomyopathy, but the left ventricular reverse remodeling effect was identified only in the Chagas model5. secretion of growth factors that are able to stimulate cell survival and In this sense, it is not...

Full description

Saved in:
Bibliographic Details
Published in:Revista brasileira de cirurgia cardiovascular 2020-01, Vol.35 (4), p.VIII-XI
Main Authors: Machado-Júnior, Paulo André Bispo, Blume, Gustavo Gavazzoni, Francisco, Julio César, Guarita-Souza, Luiz César
Format: Article
Language:English
Subjects:
Bone marrow
Cardiology
Cardiomyocytes
Cardiomyopathy
Cell adhesion & migration
Cell- and Tissue-Based Therapy
Collagen
Growth factors
Heart
Heart attacks
Heart failure
Heart Failure - therapy
Heart surgery
Humans
Hydrogels
Hypotheses
Nanoparticles
Regeneration
Stem cells
Transplants & implants
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The functional benefits were identified in both models of transmural infarction and Chagasic cardiomyopathy, but the left ventricular reverse remodeling effect was identified only in the Chagas model5. secretion of growth factors that are able to stimulate cell survival and In this sense, it is not a current consensus status that the proliferation, and the production of angiogenic factors can stimulate mechanism of action of SC occurs through the differentiation the formation of new cardiac vessels in the ischemic area, while the into cardiomyocytes; other mechanisms such as paracrine and secretion of prostaglandin E2, nitric oxide, and transforming growth immunomodulatory effects had been more accepted recently. [...]hydrogels-based approaches for tissue engineering are also a promising alternative for cardiac regeneration in models of HF. [...]the most important factor to be considered when using a cell-based approach to the treatment of HF is related to its etiology and the underlying pathologies, defining whether it is fibrotic, ischemic, idiopathic, and/or inflammatory dilated myocardiopathy.
ISSN:1678-9741
0102-7638
1678-9741
DOI:10.21470/1678-9741-2020-0362